Drug Profile

Research programme: antiviral therapies - Kino Pharma

Latest Information Update: 26 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kino Pharma
Class Anti-infectives; Anti-inflammatories; Antivirals; Eye disorder therapies; Skin disorder therapies; Small molecules
Mechanism of Action Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 May 2026 Antiviral therapies are still in preclinical trials for Condylomata acuminata in Japan (Kino Pharma pipeline, May 2026)
26 May 2026 Antiviral therapies are still in preclinical trials for Keratoconjunctivitis in Japan (Kino Pharma pipeline, May 2026)
16 Mar 2021 Preclinical trials in Condylomata acuminata in Japan (unspecified route), prior to March 2021 (Kino Pharma pipeline, March 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com